YAP1 and metabolic disease: To investigate whether obesity‐induced metabolic disorders mediate the interaction between O‐GlcNAcylation and deubiquitylation of YAP, influencing therapy responses in triple‐negative breast cancer, we established stable EIF3H knockdown (shEIF3H) as well as CRISPR/Cas9‐mediated EIF3H knockout (EIF3H KO) in MDA‐MB‐231 and 4T1 cell lines (Figure S8A, Supporting Information).